Healthcare provider profile · identity verified

Kyle Severinsen, MD

Internal Medicine · POST FALLS, ID · NPI 1396108304

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	429	143
Levothyroxine Sodium	Levothyroxine Sodium	288	94
Lisinopril	Lisinopril	225	71
Losartan Potassium	Losartan Potassium	219	78
Gabapentin	Gabapentin	197	56
Amlodipine Besylate	Amlodipine Besylate	188	68
Omeprazole	Omeprazole	186	64
Tamsulosin Hcl	Tamsulosin Hcl	180	59
Rosuvastatin Calcium	Rosuvastatin Calcium	166	62
Metoprolol Succinate	Metoprolol Succinate	143	47
Duloxetine Hcl	Duloxetine Hcl	140	36
Albuterol Sulfate Hfa	Albuterol Sulfate	134	45
Metformin Hcl	Metformin Hcl	110	36
Eliquis	Apixaban	98	26
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	96	27
Pantoprazole Sodium	Pantoprazole Sodium	95	33
Metformin Hcl Er	Metformin Hcl	94	32
Carvedilol	Carvedilol	90	29
Trazodone Hcl	Trazodone Hcl	89	30
Hydrochlorothiazide	Hydrochlorothiazide	85	31
Simvastatin	Simvastatin	85	30
Escitalopram Oxalate	Escitalopram Oxalate	78	27
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	75	20
Jardiance	Empagliflozin	74	24
Montelukast Sodium	Montelukast Sodium	73	22
Tramadol Hcl	Tramadol Hcl	69	25
Allopurinol	Allopurinol	67	26
Zolpidem Tartrate	Zolpidem Tartrate	63	23
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	60	15
Alendronate Sodium	Alendronate Sodium	58	15
Fluoxetine Hcl	Fluoxetine Hcl	58	18
Clopidogrel	Clopidogrel Bisulfate	56	18
Potassium Chloride	Potassium Chloride	54	22
Citalopram Hbr	Citalopram Hydrobromide	52	17
Ezetimibe	Ezetimibe	52	19
Sertraline Hcl	Sertraline Hcl	52	18
Meloxicam	Meloxicam	51	20
Ozempic	Semaglutide	51	suppressed
Pravastatin Sodium	Pravastatin Sodium	49	18
Telmisartan	Telmisartan	48	15
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	45	14
Prednisone	Prednisone	44	suppressed
Irbesartan	Irbesartan	42	12
Spironolactone	Spironolactone	40	15
Celecoxib	Celecoxib	37	12
Furosemide	Furosemide	37	17
Finasteride	Finasteride	36	11
Synthroid	Levothyroxine Sodium	36	11
Methocarbamol	Methocarbamol	35	13
Bupropion Xl	Bupropion Hcl	34	suppressed
Estradiol	Estradiol	33	12
Mounjaro	Tirzepatide	33	suppressed
Fenofibrate	Fenofibrate	32	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	32	11
Metoprolol Tartrate	Metoprolol Tartrate	32	13
Diclofenac Sodium	Diclofenac Sodium	28	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	28	suppressed
Glipizide	Glipizide	27	suppressed
Glipizide Er	Glipizide	27	suppressed
Lorazepam	Lorazepam	26	12
Mirtazapine	Mirtazapine	26	suppressed
Buspirone Hcl	Buspirone Hcl	25	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	25	suppressed
Xarelto	Rivaroxaban	25	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	24	11
Venlafaxine Hcl Er	Venlafaxine Hcl	24	suppressed
Atenolol	Atenolol	23	suppressed
Clonazepam	Clonazepam	23	suppressed
Famotidine	Famotidine	23	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	23	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	22	suppressed
Tizanidine Hcl	Tizanidine Hcl	21	suppressed
Alprazolam	Alprazolam	20	suppressed
Chlorthalidone	Chlorthalidone	20	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	20	13
Lamotrigine	Lamotrigine	20	suppressed
Nystatin	Nystatin	20	suppressed
Azithromycin	Azithromycin	19	11
Valsartan	Valsartan	19	suppressed
Ropinirole Hcl	Ropinirole Hcl	18	suppressed
Temazepam	Temazepam	18	suppressed
Pregabalin	Pregabalin	17	suppressed
Torsemide	Torsemide	17	suppressed
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	16	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	16	suppressed
Methylprednisolone	Methylprednisolone	16	suppressed
Propranolol Hcl Er	Propranolol Hcl	16	suppressed
Testosterone Cypionate	Testosterone Cypionate	16	suppressed
Valacyclovir	Valacyclovir Hcl	16	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	15	suppressed
Donepezil Hcl	Donepezil Hcl	15	suppressed
Fluticasone Propionate	Fluticasone Propionate	15	suppressed
Lovastatin	Lovastatin	15	suppressed
Varenicline Tartrate	Varenicline Tartrate	15	suppressed
Alprazolam Xr	Alprazolam	14	suppressed
Breyna	Budesonide/Formoterol Fumarate	14	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	14	suppressed
Novolin N	Insulin Nph Human Isophane	14	suppressed
Ondansetron Hcl	Ondansetron Hcl	14	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	14	suppressed
Oxycodone Hcl	Oxycodone Hcl	14	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	13	suppressed
Benazepril Hcl	Benazepril Hcl	13	suppressed
Glimepiride	Glimepiride	13	suppressed
Myrbetriq	Mirabegron	13	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	13	suppressed
Propranolol Hcl	Propranolol Hcl	13	suppressed
Rasagiline Mesylate	Rasagiline Mesylate	13	suppressed
Testosterone	Testosterone	13	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	13	suppressed
Breo Ellipta	Fluticasone/Vilanterol	12	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	12	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	12	suppressed
Warfarin Sodium	Warfarin Sodium	12	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	11	suppressed
Clonidine Hcl	Clonidine Hcl	11	suppressed
Efavirenz-Emtric-Tenofov Disop	Efavirenz/Emtricit/Tenofovr Df	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error